logo
logo
SIGNAL-DRIVEN SALES

Turn Funding Signals into Pipeline

Fundz analyzes real-time funding events through YOUR lens to surface companies most likely to buy — with the “why now” built in.

10–25 ICP-matched leads daily • Buyer-intent scoring • No duplicates
Every plan includes:
✓Signal-Driven Leads Based on YOUR ICP
✓Slack + Chrome real-time alerts
✓No duplicates — only new events
INDUSTRY FIRST

Ambagon Therapeutics Launches With $85 Million Series A To Advance Pioneering Molecular Glue Platform And Progress Pipeline

Jan 06, 2022•over 3 years ago

Amount Raised

$85 Million

Round Type

series a

San Francisco

Description

Ambagon Therapeutics, a biotechnology company unlocking intrinsically disordered proteins and other difficult-to-target protein classes, today announced an $85 million Series A to augment its drug discovery platform and to advance its pipeline of molecular glues.

Company Information

Company

Ambagon Therapeutics

Location

San Francisco, California, United States

About

target complexes. These molecular glue stabilizers amplify native biology to restore or inhibit target function, potentiate target activity, or promote or block target degradation. Ambagon’s initial focus is on oncology, with five programs in discovery. It has locations in San Carlos, California, and Eindhoven, the Netherlands.

FundzWatch™ Score

78
Medium Activity

Funding Insights

Based on industry data
Tech investment trends
83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech